Logo image of BLCO

BAUSCH + LOMB CORP (BLCO) Stock News

NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD

10.9  -0.47 (-4.13%)

After market: 10.97 +0.07 (+0.64%)

BLCO Latest News, Press Relases and Analysis

News Image
7 days ago - Chartmill

Wednesday's session: gap up and gap down stocks

Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Mentions: WNC SIMO VICR RGLS ...

News Image
10 hours ago - Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such...

News Image
6 days ago - Bloomberg

Crypto Influencer Anthony ‘Pomp’ Pompliano-Led SPAC Files for IPO

A blank-check company led by Anthony Pompliano, a cryptocurrency influencer and podcaster, has filed for an initial public offering to raise $200 million.

News Image
6 days ago - StockStory

Why Bausch + Lomb (BLCO) Shares Are Falling Today

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall Street's estimates, leading to an EPS miss. On the other hand, it was good to see Bausch + Lomb provide full-year revenue guidance that slightly beat analysts' expectations, although raising full-year revenue guidance after missing on revenue often raises questions. Overall, this quarter could have been better.

News Image
7 days ago - Zacks Investment Research

Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

News Image
7 days ago - StockStory

Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets, Stock Drops 10.4%

Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP loss of $0.15 per share was significantly below analysts’ consensus estimates.

News Image
7 days ago - Bausch + Lomb Corporation

Bausch + Lomb Announces First-Quarter 2025 Results

Mentions: BLCO.CA

News Image
13 days ago - Zacks Investment Research

CVS Health (CVS) Earnings Expected to Grow: Should You Buy?

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mentions: CVS

News Image
14 days ago - Zacks Investment Research

BLCO or DHR: Which Is the Better Value Stock Right Now?

BLCO vs. DHR: Which Stock Is the Better Value Option?

Mentions: DHR

News Image
14 days ago - Zacks Investment Research

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mentions: RVTY

News Image
15 days ago - Yahoo Finance

Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts?

We recently published a list of the 10 Most Undervalued Canadian Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against other undervalued Canadian stocks according to Wall Street analysts. As February was concluding, Reuters reported that Canada’s […]

Mentions: BHC TSLA

News Image
3 months ago - Stocktwits

Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Mentions: BHC VXUS VSS PPH

News Image
3 months ago - Yahoo Finance

Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent

Bausch and Lomb chairman and CEO Brent Saunders

Mentions: AAPL VZ TPG BX

News Image
3 months ago - Yahoo Finance

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.